Answers are grounded in this paper and cite their sources.
The number of patients aged 80 years and above presenting with cancer is rising rapidly. This group is characterized by physiological vulnerability, multimorbidity, polypharmacy, and diminished functional reserve, yet has been systematically excluded from the trials that define standard care. Comprehensive geriatric assessment (CGA) is a multidimensional evaluation of functional status, comorbidity, cognition, psychological state, social support, nutrition, and medication use, and has been proposed as the means of individualizing treatment where chronological age is an unreliable guide. This narrative review is centered on the assessment itself: what CGA measures, what randomized and observational evidence shows it achieves, how it can be delivered across differing resource settings including India, and where its supporting evidence is weakest. Randomized trials – principally GAP70+, GAIN and INTEGERATE – show that assessment with management reduces grade 3–5 treatment toxicity and improves patient-reported outcomes; a survival benefit has not been demonstrated, and no such trial has been restricted to patients aged 80 and above. Structured assessment outperforms unaided clinical judgment in identifying frailty. Evidence specific to the extremely elderly remains dominated by retrospective, single-center cohorts with selection bias toward fitter patients and inconsistent age thresholds; treatment-modality data are therefore summarized only insofar as CGA alters the decision, and are appraised explicitly for quality. Indian data derive almost entirely from a single tertiary center, where a majority of surveyed physicians report relying on clinical intuition rather than validated tools. For most Indian units, the practical starting point is routine screening with a validated instrument and focused assessment of domains for which local intervention exists, rather than a multidisciplinary clinic. Priorities for the field are prospective cohorts confined to the 80-plus group, recalibration of toxicity-prediction tools in Indian populations, and consensus on defining and reporting this age group.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: